Richard Benjamin Sells 24,235 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) insider Richard Benjamin sold 24,235 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $2.01, for a total value of $48,712.35. Following the completion of the transaction, the insider directly owned 919,527 shares of the company’s stock, valued at approximately $1,848,249.27. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Cerus Trading Down 8.3%

Shares of Cerus stock opened at $1.77 on Wednesday. The company has a market capitalization of $340.14 million, a price-to-earnings ratio of -22.13 and a beta of 1.51. The company has a quick ratio of 1.17, a current ratio of 1.73 and a debt-to-equity ratio of 0.62. Cerus Corporation has a 12-month low of $1.12 and a 12-month high of $2.96. The firm’s 50-day moving average price is $2.30 and its two-hundred day moving average price is $1.86.

Cerus (NASDAQ:CERS) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The company had revenue of $64.58 million during the quarter, compared to analysts’ expectations of $59.31 million. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. On average, analysts forecast that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Cibc World Markets Corp bought a new position in shares of Cerus in the 4th quarter valued at $25,000. CIBC Bancorp USA Inc. acquired a new position in Cerus in the 3rd quarter worth about $31,000. Dynamic Technology Lab Private Ltd acquired a new position in Cerus in the 1st quarter worth about $32,000. Aquatic Capital Management LLC bought a new position in Cerus in the third quarter valued at about $35,000. Finally, MML Investors Services LLC acquired a new stake in shares of Cerus during the fourth quarter valued at about $37,000. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CERS has been the subject of a number of research analyst reports. Wall Street Zen cut Cerus from a “buy” rating to a “hold” rating in a report on Saturday. TD Cowen reiterated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Cerus has an average rating of “Hold”.

Trending Headlines about Cerus

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Institutional accumulation — several hedge funds materially increased positions (AQR, Cubist, Millennium reported big additions), which provides supportive demand beneath the stock and signals some investor conviction.
• Positive Sentiment: Recent quarter: Cerus reported revenue of $64.6M versus ~$59.3M consensus, a topline beat that is constructive for fundamentals even though the company remains unprofitable.
• Neutral Sentiment: Short‑interest prints look erroneous — reported short interest shows 0 shares and 0.0 days‑to‑cover for early March; treat those figures as unreliable until exchanges correct filings.
• Neutral Sentiment: Analyst posture is mixed: one independent provider downgraded CERS to Hold recently while TD Cowen maintained a Buy earlier in January — consensus sits near “Hold,” so no clear new catalyst from Street coverage.
• Negative Sentiment: Significant insider selling across leadership — multiple insiders disclosed sales Mar. 5–9 that reduced insider stakes by low‑ to mid‑single digits (CEO William Greenman, CFO Kevin D. Green, COO Vivek Jayaraman, director Richard J. Benjamin, Chrystal Jensen). These filings increase circulating supply and likely drove negative sentiment. CEO filing: Read More.; CFO filing: Read More.; Richard Benjamin filings: Read More..

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.